A mini review on recent progress of microfluidic systems for antibody development
Kobra Omidfar1,2, Sohiela Kashanian3,4
1Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, P.O. Box 14395/1179, Tehran, IR Iran.
Journal of Diabetes and Metabolic Disorders
|June 27, 2024
Summary
Microfluidics offers a promising approach to streamline antibody discovery, addressing limitations of traditional methods. This review highlights valve, microwell, and droplet platforms for developing antibodies efficiently.
Area of Science:
- Biomedical Research
- Immunotechnology
- Biotechnology
Background:
- Monoclonal antibody production faces challenges like lengthy screening and low efficiency.
- Traditional hybridoma and antibody engineering techniques have inherent limitations.
- Microfluidics presents novel solutions for antibody isolation and screening.
Purpose of the Study:
- To review recent advancements in microfluidic techniques for antibody development.
- To analyze the application of microfluidic platforms in antibody discovery.
- To summarize key findings and discuss future directions in microfluidic antibody research.
Main Methods:
- Systematic literature search across major scientific databases (Web of Science, Scopus, PubMed, Google Scholar, Science Direct).
- Analysis of seventy peer-reviewed articles focusing on microfluidic applications in antibody development.
- Categorization of microfluidic platforms into valves, microwells, and droplets.
Main Results:
- Seventy relevant papers were identified and analyzed.
- Microfluidic platforms (valves, microwells, droplets) show significant application in antibody development via hybridoma and phage display.
- Key findings and applications of these platforms are summarized and discussed.
Conclusions:
- Microfluidics can significantly streamline antibody discovery processes.
- Current microfluidic applications are primarily laboratory-based.
- Further research is needed to enhance reliability, accuracy, and cost-effectiveness for broader adoption.
